Literature DB >> 35168293

Expanding the spectrum of mesenchymal neoplasms with NR1D1-rearrangement.

Maribel D Lacambra1, Cristina R Antonescu2, Chit Chow1, Wang Kei Chiu3, Elizabeth G Demicco4,5, Peter C Ferguson6,7, David Swanson4,5, Ka-Fai To1, Lei Zhang1, Brendan C Dickson4,5.   

Abstract

Undifferentiated mesenchymal neoplasms can be morphologically subclassified based on cell shape; epithelioid tumors may be diagnostically challenging, particularly since they can show morphologic and immunohistochemical overlap with epithelial neoplasms. Following the recent report of an NR1D1::MAML1 gene fusion in an undifferentiated pediatric neoplasm, we performed a retrospective archival review and identified four additional cases of undifferentiated mesenchymal neoplasms with NR1D1-rearrangement. All four tumors occurred in adult women. The tumors involved superficial and/or deep soft tissues of the extremities or abdomen. Morphologically, they showed a spectrum of overlapping features. In addition to epithelioid cells, two cases also had a prominent spindle cell component. Two cases also had admixed polygonal cells containing prominent cytoplasmic vacuoles with amorphous debris. The immunophenotype was nonspecific but all cases had at least focal keratin expression; this was extensive in two tumors. Targeted RNA-sequencing revealed two cases each with NR1D1::MAML1 and NR1D1::MAML2 gene fusions. One patient developed lung and liver metastases, and one patient required amputation due to multifocal disease and underlying bone involvement. This study confirms undifferentiated NR1D1-rearranged sarcoma represents a distinct mesenchymal neoplasm with an epithelioid morphology and potential for aggressive behavior. Further, we offer new insight into the spectrum of clinical, morphologic, immunohistochemical, and molecular findings possible in these rare neoplasms. An awareness of this entity is especially important given the potential for misclassification as a carcinoma.
© 2022 Wiley Periodicals LLC.

Entities:  

Keywords:  MAML1; MAML2; NR1D1; epithelioid; fusion; soft tissue

Mesh:

Substances:

Year:  2022        PMID: 35168293      PMCID: PMC9195160          DOI: 10.1002/gcc.23032

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   4.263


  44 in total

1.  Novel BCOR-MAML3 and ZC3H7B-BCOR Gene Fusions in Undifferentiated Small Blue Round Cell Sarcomas.

Authors:  Katja Specht; Lei Zhang; Yun-Shao Sung; Marisa Nucci; Sarah Dry; Sumathi Vaiyapuri; Gunther H S Richter; Christopher D M Fletcher; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2016-04       Impact factor: 6.394

2.  Most gene fusions in cancer are stochastic events.

Authors:  Bertil Johansson; Fredrik Mertens; Tommy Schyman; Jonas Björk; Nils Mandahl; Felix Mitelman
Journal:  Genes Chromosomes Cancer       Date:  2019-03-18       Impact factor: 5.006

3.  EWSR1 rearrangements in sclerosing epithelioid fibrosarcoma.

Authors:  Leona A Doyle; Jason L Hornick
Journal:  Am J Surg Pathol       Date:  2013-10       Impact factor: 6.394

4.  A Distinct Malignant Epithelioid Neoplasm With GLI1 Gene Rearrangements, Frequent S100 Protein Expression, and Metastatic Potential: Expanding the Spectrum of Pathologic Entities With ACTB/MALAT1/PTCH1-GLI1 Fusions.

Authors:  Cristina R Antonescu; Narasimhan P Agaram; Yun-Shao Sung; Lei Zhang; David Swanson; Brendan C Dickson
Journal:  Am J Surg Pathol       Date:  2018-04       Impact factor: 6.394

5.  Identification of new human mastermind proteins defines a family that consists of positive regulators for notch signaling.

Authors:  Sey-En Lin; Toshinao Oyama; Takahiro Nagase; Kenichi Harigaya; Motoo Kitagawa
Journal:  J Biol Chem       Date:  2002-10-16       Impact factor: 5.157

Review 6.  What is new in epithelioid soft tissue tumors?

Authors:  Abbas Agaimy
Journal:  Virchows Arch       Date:  2019-11-04       Impact factor: 4.064

7.  SMARCB1/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas.

Authors:  Piergiorgio Modena; Elena Lualdi; Federica Facchinetti; Lisa Galli; Manuel R Teixeira; Silvana Pilotti; Gabriella Sozzi
Journal:  Cancer Res       Date:  2005-05-15       Impact factor: 12.701

8.  BCOR upregulation in a poorly differentiated synovial sarcoma with SS18L1-SSX1 fusion-A pathologic and molecular pitfall.

Authors:  Yu-Chien Kao; Yun-Shao Sung; Lei Zhang; Samuel Kenan; Samuel Singer; William D Tap; David Swanson; Brendan C Dickson; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2017-01-04       Impact factor: 5.006

9.  Fusion of PAX3 to a member of the forkhead family of transcription factors in human alveolar rhabdomyosarcoma.

Authors:  D N Shapiro; J E Sublett; B Li; J R Downing; C W Naeve
Journal:  Cancer Res       Date:  1993-11-01       Impact factor: 12.701

10.  First report of t(5;11) KMT2A-MAML1 fusion in de novo infant acute lymphoblastic leukemia.

Authors:  Sneha Tandon; Mary Shago; Scott Davidson; Nisha Kanwar; Fabio Fuligni; Adam Shlien; James Whitlock; Anita Villani; Oussama Abla
Journal:  Cancer Genet       Date:  2020-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.